Growth Metrics

Bioventus (BVS) Total Current Liabilities (2020 - 2026)

Bioventus filings provide 6 years of Total Current Liabilities readings, the most recent being $160.4 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 23.77% to $160.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $160.4 million, a 23.77% decrease, with the full-year FY2025 number at $160.4 million, down 23.77% from a year prior.
  • Total Current Liabilities hit $160.4 million in Q4 2025 for Bioventus, down from $161.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $304.0 million in Q4 2022 to a low of $149.0 million in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $177.3 million (2023), compared with a mean of $191.6 million.
  • Biggest five-year swings in Total Current Liabilities: soared 79.44% in 2022 and later tumbled 44.22% in 2023.
  • Bioventus' Total Current Liabilities stood at $180.9 million in 2021, then surged by 68.1% to $304.0 million in 2022, then tumbled by 42.27% to $175.5 million in 2023, then increased by 19.89% to $210.4 million in 2024, then dropped by 23.77% to $160.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $160.4 million (Q4 2025), $161.8 million (Q3 2025), and $185.7 million (Q2 2025) per Business Quant data.